Swedish Orphan Biovitrum
290
SEK
-0.21 %
SOBI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
5 following
-0.21%
-9.15%
-4.86%
+4.17%
+8.61%
+20.13%
+33.4%
+90.29%
+507.73%
www.sobi.com/en/investors
Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.
Revenue
22.12B
EBIT %
18.38 %
P/E
38.82
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
SOBI
Daily low / high price
289.4 / 296.8
SEK
Market cap
103.24B SEK
Turnover
206.24M SEK
Volume
709K
Financial calendar
Extraordinary general meeting
2024-12-11
Annual report
2025-02-05
Interim report
2025-04-29
General meeting
2025-05-08
Interim report
2025-07-15
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Investor | 34.5 % | 34.5 % |
| Morgan Stanley Smith Barney | 9.8 % | 9.8 % |
| Fjärde AP-fonden | 5.8 % | 5.8 % |
| AMF - Försäkring Och Fonder | 4.3 % | 4.3 % |
| State Street Bank and Trust | 4.2 % | 4.2 % |
| JP Morgan Chase Bank NA | 3.2 % | 3.2 % |
| Northern Trust Company, London Branch | 3.1 % | 3.1 % |
| Swedbank Robur fonder | 3.0 % | 3.0 % |
| Handelsbanken Fonder | 2.5 % | 2.5 % |
| BNY Mellon Na (Former Mellon), W9 | 1.5 % | 1.5 % |
ShowingAll content types
Kallelse till extra bolagsstämma i Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB: David Meek föreslås som ny styrelseordförande i Sobi
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools